Abu Dhabi – Mubasher: Julphar Pharmaceuticals has said that its subsidiary Gulf Inject has signed a partnership agreement with Zulekha Healthcare Group.
The deal involves local distribution and marketing with Zulekha, which specialises in providing healthcare services across Dubai and Sharjah, Julphar said in a statement.
This new partnership is in line with Julphar’s expansion strategy, unveiled in May, which also includes opening the first cancer-drug-production facility in Abu Dhabi.
Julphar last reported a 44.2% drop in profits to AED 44.1 million in the first quarter of 2017, compared to AED 79 million in the year-ago period.
